Arterra Bioscience Logo

Arterra Bioscience

ABS | XMIL

Overview

Corporate Details

ISIN(s):
IT0005386369
LEI:
8156006E67B9AB95E292
Country:
Italy
Address:
VIA BENEDETTO BRIN, 69, 80142 NAPOLI
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Arterra Bioscience is a green biotechnology company, founded in 2004, that specializes in the research, development, and production of sustainable, high-value active ingredients. The company creates innovative solutions for various sectors, including the cosmetics, nutraceutical, pharmaceutical, agriculture, and food industries. Utilizing proprietary technologies such as in vitro plant cell cultures, bioassays, and recombinant protein production, Arterra develops stable, preservative-free raw materials derived from natural sources. Its production process focuses on creating bio-sustainable industrial products through in vitro cultures and extraction.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Arterra Bioscience. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-01 17:59
M&A Activity
ARTERRA BIOSCIENCE S.P.A. HA CEDUTO L’INTERA PARTECIPAZIONE DETENUTA NEL CAPITA…
Italian 245.2 KB
2025-07-31 16:27
Regulatory News Service
ARTERRA BIOSCIENCE S.P.A. HA CEDUTO L’INTERA PARTECIPAZIONE DETENUTA NEL CAPITA…
Italian 244.9 KB
2025-07-18 13:28
Earnings Release
ARTERRA BIOSCIENCE S.P.A.: FATTURATO AL 30 GIUGNO 2025 PARI A CIRCA 2,6 MILIONI…
Italian 256.6 KB
2025-06-23 17:43
Director's Dealing
Arterra - Allegato A (Manager) - Notifica di comunicazione
Italian 133.7 KB
2025-06-23 17:36
Major Shareholding Notification
ARTERRA - CAMBIAMENTO SOSTANZIALE IN MATERIA DI ASSETTI PROPRIETARI
Italian 254.7 KB
2025-06-12 21:25
Report Publication Announcement
ARTERRA BIOSCIENCE S.P.A. PARTECIPA ALL’EVENTO “FINANCIAL GALÀ” ORGANIZZATO DA …
Italian 350.6 KB
2025-05-19 19:14
Capital/Financing Update
ARTERRA - FINANZIAMENTO E CONCESSIONE AGEVOLAZIONI PER IL PROGETTO “SmartLAB 2.…
Italian 319.2 KB
2025-05-06 11:21
Earnings Release
ARTERRA - FATTURATO AL 31 MARZO 2025 PARI A CIRCA 1,3 MILIONI DI EURO
Italian 253.5 KB
2025-04-29 13:44
Post-Annual General Meeting Information
ARTERRA BIOSCIENCE - ASSEMBLEA ORDINARIA DEGLI AZIONISTI
Italian 347.4 KB
2025-04-23 18:40
Pre-Annual General Meeting Information
ARTERRA - DEPOSITO E PUBBLICAZIONE DELLE LISTE PER LA NOMINA DEI MEMBRI DEL CON…
Italian 302.5 KB
2025-04-03 19:19
Pre-Annual General Meeting Information
ARTERRA - PUBBLICAZIONE AVVISO DI CONVOCAZIONE DI ASSEMBLEA ORDINARIA
Italian 340.4 KB
2025-03-28 11:49
Earnings Release
Arterra - Il Consiglio di Amministrazione ha approvato il progetto di Bilancio …
Italian 297.4 KB
2025-02-13 12:35
Earnings Release
ARTERRA BIOSCIENCE S.P.A.: FATTURATO AL 31 DICEMBRE 2024 PARI A 4,2 MILIONI DI …
Italian 248.2 KB
2024-11-04 11:58
Earnings Release
ARTERRA - FATTURATO AL 30 SETTEMBRE 2024 PARI A CIRCA 2.8 MILIONI DI EURO
Italian 248.4 KB
2024-10-02 18:30
Environmental & Social Information
ARTERRA - CONCESSIONE AGEVOLAZIONI
Italian 238.1 KB

Automate Your Workflow. Get a real-time feed of all Arterra Bioscience filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Arterra Bioscience via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
1NKEMIA Logo
Offers contract R&D, develops tech platforms, and invests in life sciences ventures.
Spain IKM
2cureX AB Logo
Tests cancer drugs on patient-derived micro-tumors for personalized oncology treatments.
Sweden 2CUREX
4SC AG Logo
Developing epigenetic small-molecule drugs for cancers with high unmet medical needs.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using an OMV platform for major infectious diseases.
Sweden ABERA
ABIVAX Logo
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
France ABVX
Abliva Logo
A clinical-stage biotech developing medicines for rare primary mitochondrial diseases.
Sweden ABLI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Acticor Biotech Logo
Biopharma developing first-in-class drugs for acute stroke and other thrombotic diseases.
France ALACT
Active Biotech Logo
Develops immunotherapies for cancer and inflammatory diseases with significant unmet needs.
Sweden ACTI
Addex Therapeutics Ltd Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland ADXN